



BSI Standards Publication

## Biotechnology — Ancillary materials present during the production of cellular therapeutic products

---

Part 3: Best practice guidance for ancillary material users

## National foreword

This Published Document is the UK implementation of ISO/TS 20399-3:2018.

The UK participation in its preparation was entrusted to Technical Committee BTI/1, Biotechnologies.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2018  
Published by BSI Standards Limited 2018

ISBN 978 0 580 94263 1

ICS 07.080

**Compliance with a British Standard cannot confer immunity from legal obligations.**

This Published Document was published under the authority of the Standards Policy and Strategy Committee on 31 December 2018.

### Amendments/corrigenda issued since publication

Date	Text affected
------	---------------

---

---

---

**Biotechnology — Ancillary materials  
present during the production of  
cellular therapeutic products —**

**Part 3:  
Best practice guidance for ancillary  
material users**

*Biotechnologie — Matériaux auxiliaires présents lors de la production  
de produits thérapeutiques cellulaires —*

*Partie 3: Lignes directrices de bonne pratique pour les utilisateurs de  
matériaux auxiliaires*





**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2018. Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
Ch. de Blandonnet 8 • CP 401  
CH-1214 Vernier, Geneva, Switzerland  
Tel. +41 22 749 01 11  
Fax +41 22 749 09 47  
copyright@iso.org  
www.iso.org

## Contents

Page

Foreword.....	iv
Introduction.....	v
<b>1 Scope.....</b>	<b>1</b>
<b>2 Normative references.....</b>	<b>2</b>
<b>3 Terms and definitions.....</b>	<b>2</b>
<b>4 Abbreviated terms.....</b>	<b>2</b>
<b>5 Quality declarations for manufactured biological materials used in the manufacture of a cellular therapeutic product.....</b>	<b>3</b>
<b>6 Evaluation criteria and mitigation of risk.....</b>	<b>4</b>
6.1 Evaluation criteria.....	4
6.2 Mitigation of risk.....	6
6.2.1 Scientific approach.....	6
6.2.2 Supplier audit and questionnaires.....	7
6.2.3 Risk assessments.....	8
<b>7 Characterization of biological materials.....</b>	<b>9</b>
<b>8 Managing changes to materials.....</b>	<b>10</b>
8.1 Impact of changes to materials.....	10
8.2 Supplier agreement considerations.....	10
<b>Bibliography.....</b>	<b>11</b>

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

This document was prepared by Technical Committee ISO/TC 275, *Biotechnology*.

A list of all parts in the ISO/TS 20399 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at [www.iso.org/members.html](http://www.iso.org/members.html).

## Introduction

Ancillary materials (AMs) are materials that come into contact with the cellular therapeutic product during the manufacturing process, but are not intended to be in the final product.

AMs include culture media and growth factors, among other biological and non-biological components. They can be a complex mixture of many components and variation in their lot-to-lot composition can hamper the ability to produce a consistent cellular therapeutic product with specified quality attributes.

As such, AMs can have implications with regard to the safety and effectiveness of a cellular therapeutic product. Appropriate control of ancillary material is determined by a risk-based approach.

This document specifies guidelines to AM users on best practice considerations for use of AMs, particularly those of biological origin, in the manufacture of cellular therapeutic product and contributes to their control by suppliers and users of such materials.

The ISO/TS 20399 series provides general requirements and guidance regarding ancillary materials to maintain a high level of lot-to-lot consistency, as well as the accompanying documentation, so that consistent ancillary material (AM) products and documentation provided by the AM suppliers can help AM users.

Currently in preview, click buy full version

# Biotechnology — Ancillary materials present during the production of cellular therapeutic products —

## Part 3: Best practice guidance for ancillary material users

### 1 Scope

This document provides guidance for ancillary material (AM) users. It is applicable to cellular therapeutic products, including those gene therapy products whereby cells form part of the final product. It does not apply to products without cells.

This document focuses primarily on ancillary materials (AMs) of biological (human and animal) origin and their potential impurities and contaminants.

NOTE 1 The decision chart in Figure 1 illustrates the rationale underlying the scope of this document.

However, diverse biological sources, including plants, insects and marine organisms, can also be used in the development of a cellular therapeutic product. Therefore the fundamental principles of risk management also apply for these sources of AMs.

This document does not cover the selection, assessment or control of starting materials and excipients. However, it is anticipated that these are still covered by general risk management procedures.

This document is applicable for users at all stages of clinical development and supply; however maximum benefits can be gained by the implementation of the recommendations in the early stages of development.

NOTE 2 International, regional or national regulations or requirements can also apply to specific topics covered in this document.